Alvotech – Pioneering Biosimilars, Enriching Global Healthcare Access, and Fostering a Culture of Purpose-Driven Innovation

Alvotech – Pioneering Biosimilars, Enriching Global Healthcare Access, and Fostering a Culture of Purpose-Driven Innovation

Biologic medicines, or biologics, are crafted through biotechnology within living systems, representing large and intricate molecules that demand advanced characterization techniques and are typically administered through injections or infusions. In contrast, conventional medicines are typically composed of chemically synthesized small molecules, easily characterized and commonly delivered in pill or capsule form. The progress and evolution of biologics stem from groundbreaking research, offering innovative and transformative treatments across various therapeutic areas for numerous diseases.

While biologics stand as groundbreaking treatment options for patients grappling with debilitating and life-threatening diseases, they often come with high costs, leading to limited patient access. Fortunately, a more accessible alternative is emerging for many patients dependent on biologic treatments: biosimilars. Biosimilars are biologic medicines that closely resemble previously approved reference biologics already available in the market. Biosimilars play a crucial role by introducing competition to the market, thereby expanding patient access to essential medicines, similar to the impact of generic medications over 35 years ago. This competition not only benefits health systems and payers but also provides a more cost-effective alternative for patients. The advent of biosimilars holds the promise of enhancing access to life-changing biologics for individuals who might otherwise struggle to afford them.

Alvotech stands as a company deeply attuned to the transformative impact that biologic medicines have had on the healthcare landscape. From insulin to vaccines and monoclonal antibody cancer therapies, biologics have redefined disease treatment, enhancing the lives of patients worldwide. Alvotech is dedicated to expanding the global accessibility of these vital biologic medicines by specializing in the development and manufacturing of high-quality, cost-competitive biosimilars.

The company is guided by a steadfast commitment to the potential of biosimilars, a commitment that underpins its approach, culture, and the profound sense of purpose motivating its team. Alvotech operates with a clear mission to work diligently and efficiently toward making biosimilar medicines more widely available. By reducing costs associated with existing treatments, Alvotech envisions contributing to the sustainability of healthcare systems and redirecting resources to support the development of next-generation, innovative branded biologics.

Q.What Sets Alvotech Apart?

At Alvotech, what truly sets them apart is their unwavering dedication to the field of biosimilars. With a robust team comprising over 900 professionals distributed across multiple countries, Alvotech operates as a cohesive force, bound by a collective commitment to improving lives through expanded access to affordable biologic medicines. This shared purpose serves as the cornerstone of their organizational culture, uniting diverse expertise to foster insights, creativity, and a resolute determination to collectively achieve their mission.

The driving force behind Alvotech's success lies in the passion, motivation, and empowerment of its workforce. This team not only mirrors the diversity of the wider market they serve but also operates with a high level of cohesion and engagement. Alvotech brings together some of the brightest minds in the industry, strategically investing in both scientific advancements and the development of their people. This holistic approach ensures that they fulfill their promise to partners and patients on a global scale, delivering innovative and accessible biosimilar solutions.

Advancing Access, Enriching Lives

Guided by scientific innovation, fueled by unwavering passion, and dedicated to the realm of biosimilars, Alvotech stands committed to enhancing treatment options globally. The company consistently assesses additional opportunities in its pipeline, aiming to provide a strategic and comprehensive array of therapeutic solutions to patients worldwide. Collaborating with Alvotech opens doors to a partner deeply devoted to developing and manufacturing top-tier, cost-competitive biosimilars.

Alvotech actively seeks commercial partners who share their fervor for expanding biosimilar access to patients globally and possess profound expertise to transform the promise of biosimilars into reality. The company is receptive to forming partnerships and licensing agreements for their biosimilar assets on a global scale. They firmly believe that through collaborative efforts, partners can harness the collective strengths each brings to the table, creating substantial value for their customers.

Róbert Wessman | Founder & CEO       

Róbert Wessman is the visionary behind Alvotech, known for his passion for improving patient lives and the global healthcare ecosystem, his unwavering focus and his ability to successfully combine operational efficiency with growth through strategic acquisitions. He recognized the potential early on for locating a biotechnology company in Iceland and founded Alvotech in 2013, further contributing to the pharmaceutical industry growth there.

Prior to founding Alvotech, Róbert Wessman transformed Actavis, originally a small domestic pharmaceutical company, into the fourth largest generics company in the world within seven years as CEO. He also founded Alvogen in 2009 as a US-based CMO prior to growing it into a top global generics company over the course of 6 years. In total over his more than 20-year career in the pharmaceutical industry, he has led over 50 strategic acquisitions and partnerships and established operations in over 60 countries around the world.

"In our dedication to biosimilars, we strive to make a difference—creating value for partners and unlocking access to transformative treatments worldwide."